These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Complex serology and immune response of mice to variant high-molecular-weight O polysaccharides isolated from Pseudomonas aeruginosa serogroup O2 strains. Hatano K; Pier GB Infect Immun; 1998 Aug; 66(8):3719-26. PubMed ID: 9673254 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of a Moustafa DA; DiGiandomenico A; Raghuram V; Schulman M; Scarff JM; Davis MR; Varga JJ; Dean CR; Goldberg JB Infect Immun; 2023 Dec; 91(12):e0024723. PubMed ID: 37991349 [TBL] [Abstract][Full Text] [Related]
8. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa. Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788 [TBL] [Abstract][Full Text] [Related]
9. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate). Hatano K; Goldberg JB; Pier GB Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730 [TBL] [Abstract][Full Text] [Related]
10. Protection of immunosuppressed mice against translocation of Pseudomonas aeruginosa from the gut by oral immunization with recombinant Pseudomonas aeruginosa outer membrane protein I expressing Salmonella dublin. Toth A; Schödel F; Duchêne M; Massarrat K; Blum B; Schmitt A; Domdey H; von Specht BU Vaccine; 1994 Oct; 12(13):1215-21. PubMed ID: 7839727 [TBL] [Abstract][Full Text] [Related]
12. Protection against oral challenge three months after i.v. immunization of BALB/c mice with live Aro Salmonella typhimurium and Salmonella enteritidis vaccines is serotype (species)-dependent and only partially determined by the main LPS O antigen. Hormaeche CE; Mastroeni P; Harrison JA; Demarco de Hormaeche R; Svenson S; Stocker BA Vaccine; 1996 Mar; 14(4):251-9. PubMed ID: 8744548 [TBL] [Abstract][Full Text] [Related]
13. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605 [TBL] [Abstract][Full Text] [Related]
14. Antibody responses to lipid A, core, and O sugars of the Pseudomonas aeruginosa lipopolysaccharide in chronically infected cystic fibrosis patients. Kronborg G; Fomsgaard A; Galanos C; Freudenberg MA; Høiby N J Clin Microbiol; 1992 Jul; 30(7):1848-55. PubMed ID: 1378455 [TBL] [Abstract][Full Text] [Related]
15. Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06. Pier GB; Koles NL; Meluleni G; Hatano K; Pollack M Infect Immun; 1994 Apr; 62(4):1137-43. PubMed ID: 8132318 [TBL] [Abstract][Full Text] [Related]
16. Intranasal Peptide-Based FpvA-KLH Conjugate Vaccine Protects Mice From Sen-Kilic E; Blackwood CB; Boehm DT; Witt WT; Malkowski AC; Bevere JR; Wong TY; Hall JM; Bradford SD; Varney ME; Damron FH; Barbier M Front Immunol; 2019; 10():2497. PubMed ID: 31708925 [No Abstract] [Full Text] [Related]
17. Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease. Currie CG; McCALLUM K; Poxton IR J Med Microbiol; 2001 Apr; 50(4):345-354. PubMed ID: 11289520 [TBL] [Abstract][Full Text] [Related]
18. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100 [TBL] [Abstract][Full Text] [Related]